Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

Fig. 3

The main evolution of CAR T cell therapy for treating AML. CIK, cytokine induced killer; EBV-CTL, human Epstein Barr Virus-cytotoxic lymphocyte; EGFRt, a tag derived from the epidermal growth factor receptor, is the antigen of the clinically available antibody cetuximab; DAP10, a type of natural adaptive protein, provides a costimulatory signal similar to that of CD28 [113]; ATRA, all-trans retinoic acid, a drug that up-regulates the expression of the target antigen, resulting in improved anti-leukemia activity; GoCART, a structure comprising a proliferation-deficient first generation CAR and a ligand-dependent activation switch (e.g., iMC) that efficiently eradicates CD123+ AML cells when co-stimulated with systemic rimiducid administration. iMC, inducible MyD88/CD40 is a ligand (rimiducid)-dependent costimulatory switch [114]

Back to article page